- Home
- GALT vs IMRX Comparison
GALT vs IMRX Comparison
Compare GALT & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- IMRX
- Stock Information
- Founded
- GALT 2000
- IMRX 2008
- Country
- GALT United States
- IMRX United States
- Employees
- GALT N/A
- IMRX N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- IMRX Health Care
- Exchange
- GALT Nasdaq
- IMRX Nasdaq
- Market Cap
- GALT 232.3M
- IMRX 232.9M
- IPO Year
- GALT N/A
- IMRX 2021
- Fundamental
- Price
- GALT $5.60
- IMRX $6.36
- Analyst Decision
- GALT Strong Buy
- IMRX Strong Buy
- Analyst Count
- GALT 3
- IMRX 5
- Target Price
- GALT $6.00
- IMRX $17.20
- AVG Volume (30 Days)
- GALT 348.6K
- IMRX 1.4M
- Earning Date
- GALT 11-17-2025
- IMRX 11-10-2025
- Dividend Yield
- GALT N/A
- IMRX N/A
- EPS Growth
- GALT N/A
- IMRX N/A
- EPS
- GALT N/A
- IMRX N/A
- Revenue
- GALT N/A
- IMRX N/A
- Revenue This Year
- GALT N/A
- IMRX N/A
- Revenue Next Year
- GALT N/A
- IMRX N/A
- P/E Ratio
- GALT N/A
- IMRX N/A
- Revenue Growth
- GALT N/A
- IMRX N/A
- 52 Week Low
- GALT $0.73
- IMRX $1.10
- 52 Week High
- GALT $6.55
- IMRX $10.08
- Technical
- Relative Strength Index (RSI)
- GALT 60.67
- IMRX 51.33
- Support Level
- GALT $5.04
- IMRX $6.10
- Resistance Level
- GALT $5.36
- IMRX $7.15
- Average True Range (ATR)
- GALT 0.33
- IMRX 0.50
- MACD
- GALT 0.05
- IMRX 0.07
- Stochastic Oscillator
- GALT 54.39
- IMRX 59.11
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.